Modus Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Modus Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,706	Closed	-$7.09K	–	106
2023 Q1	$7.09K	Hold	19,706	–	–	﹤0.01%	102
2022 Q4	$17.5K	Hold	19,706	–	–	0.01%	100
2022 Q3	$31K	Hold	19,706	–	–	0.02%	93
2022 Q2	$40K	Hold	19,706	–	–	0.02%	95
2022 Q1	$46K	Hold	19,706	–	–	0.02%	97
2021 Q4	$92K	Hold	19,706	–	–	0.04%	96
2021 Q3	$150K	Hold	19,706	–	–	0.06%	98
2021 Q2	$191K	Hold	19,706	–	–	0.08%	97
2021 Q1	$163K	Buy	19,706 +4,846	+33%	+$51.2K	0.08%	94
2020 Q4	$101K	Buy	+14,860	New	+$119K	0.05%	86
2020 Q3	–	Sell	-10,000	Closed	-$63K	–	221
2020 Q2	$63K	Buy	+10,000	New	+$38.3K	0.04%	108

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Modus Advisors's SRNE Position: Q2 2023 in Review

Modus Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 19,706 shares — an estimated $7.09K sold.

Modus Advisors first reported a position in SRNE in Q2 2020 and held it in 11 quarters. The position peaked at $191K in Q2 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Modus Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Modus Advisors sold 19,706 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $7.09K.
Modus Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
Modus Advisors's Sorrento Therapeutics, Inc. position peaked at $191K in Q2 2021.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Modus Advisors's 13F filing for Q2 2023, filed 5 Jul 2023.